Navigation Links
CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007

ROCKVILLE, Md., April 4, 2007 -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies has been selected to present a poster abstract at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago Illinois, June 1-5. The poster session will take place from 8:00 am to 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of CytImmune will present the poster abstract entitled "Preliminary Results of a Phase I clinical trial of CYT-6091: A pegylated colloidal gold TNF nanomedicine.


"Acceptance to ASCO provides CytImmune the opportunity to present its research to the leading body of international oncology experts," said Dr. Lawrence Tamarkin, CEO of CytImmune Sciences. "For an emerging company, it's a chance interact with those in the field, advance science and demonstrate our role in the fight against cancer."


CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer pegylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities. To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby avoiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites. At 27 nanometers in size, CYT-6091 is able to exit the blood stream through leaky blood vessels and sequester in and around tumor sites with TNF binding to available receptors in this area. Preclinical studies indicate that CYT-6091 is then able to actively and passively target tumors, potentially delivering more drug to the site of disease with reduced side effects. The mechanism of targeting solid tumor
'"/>




Page: 1 2

Related medicine technology :

1. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: CytImmune Present ASCO Phase Clinical Trial CYT Presented June
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... New GoodBelly Brings Together Delicious, Antioxidant-Rich Fruit and ... of the Hottest Food Trends for 2008, ... Foods,Industry pioneer Steve Demos is launching GoodBelly(TM) -- ... probiotics and,antioxidant-rich fruit ( http://www.goodbelly.com ). Probiotics -- ...
... food items aimed specifically at children have a poor nutritional ... sodium - according to a detailed study of 367 products ... Obesity Reviews . , Just under 70 per cent ... drinks and bakery items - derived a high proportion of ...
... Brings New technology for On-line tracking and Document Access, ... Board, LLC,announces the launch of an automated web based ... clients to,securely log onto a website 24 hours a ... their study. The system also allows,clients to access approval ...
... CRME TSX: COM, VANCOUVER, July 14 /PRNewswire-FirstCall/ ... today announced positive clinical results from,its 90-day Phase ... statistically significant efficacy for the patient group,receiving 500mg ... The,safety data from the final analysis also shows ...
... New Tools and Features Build Upon the Trusted Experience 100 ... Families Have Come to Know, Love and Depend ... Internet,s,largest resource for new and expectant parents around the world, ... network,enables members to share and connect with each other and ...
... - Platform,s Online Content Doubled in Less Than ... scientific, technical and medical,(STM) information, today announced that ... million full-text articles., Doubling its content in ... most extensive online STM research platform. Serving the,evolving ...
Cached Medicine News:Health News:Introducing GoodBelly(TM) the New Probiotic Fruit Drink Line 2Health News:89 percent of children's food products provide poor nutritional quality 2Health News:89 percent of children's food products provide poor nutritional quality 3Health News:89 percent of children's food products provide poor nutritional quality 4Health News:Aspire IRB Announces the Launch of an Automated Web Portal System 2Health News:Cardiome Announces Positive Phase 2b Results For Oral Vernakalant 2Health News:Cardiome Announces Positive Phase 2b Results For Oral Vernakalant 3Health News:Cardiome Announces Positive Phase 2b Results For Oral Vernakalant 4Health News:Cardiome Announces Positive Phase 2b Results For Oral Vernakalant 5Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 2Health News:BabyCenter Launches Social Network for Largest Parenting Community Online 3Health News:Elsevier's "ScienceDirect" Articles Surpass Nine-Million Mark 2Health News:Elsevier's "ScienceDirect" Articles Surpass Nine-Million Mark 3
... Cage is a sport functional ... of combined ACL and PCL ... to the medial collateral ligament ... can be supported. The Hi-Impact ...
... best, the Bledsoe Extender Brace meets the physicians' ... to 86 cm) in length and up to ... easily fits patients from 5' (152 cm) to ... the patient progresses. The Bledsoe Extender is so ...
... The Bledsoe Lever Lock Knee ... quick extension lock of the arthroscopic ... to allow motion for rehabilitation or ... quickly locked "rigidly" in full extension ...
The Bledsoe Adjustable Knee Brace is designed to meet the most stringent demands of post-op care. When post-op care demands the best, the Bledsoe Adjustable Knee Brace is the physicians' preferred ch...
Medicine Products: